Amgen Snaps Up Cancer Drug Startup in $840 Million Bet
In a major move for cancer drug development, Amgen is buying Dark Blue Therapeutics for a deal worth up to $840 million. The acquisition centers on a novel therapy targeting a hard-to-treat form of leukemia.